GlassScriptPhysician profile
Casey Lynn Buncher
NPI 1891336178
$3,208.38
in general payments reported to CMS, 2019-2025
43 companies · $836 in 2025
The $836 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $77.16 · 2022: $919 · 2023: $629 · 2024: $746 · 2025: $836.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,211.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $471.75 | 2022-2025 | Breztri, Fasenra, Tezspire |
| Novo Nordisk INC | $373.58 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $277.72 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Actelion Pharmaceuticals US, INC. | $150.78 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $145.29 | 2023-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.20 | 2022-2025 | Jardiance, Synjardy, Stiolto Respimat |
| Exact Sciences Corporation | $107.67 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $105.99 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Dexcom, INC. | $101.42 | 2024-2025 | Dexcom G6 Transmitter |
| Tris Pharma INC | $85.50 | 2023-2025 | Dyanavel Xr |
| Grifols USA, LLC | $83.91 | 2022-2023 | Prolastin-C Liquid |
| Abbvie INC. | $78.19 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $78.14 | 2022-2023 | Dupixent |
| Philips North America LLC | $78.05 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $76.51 | 2022-2024 | Trintellix |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $73.37 | 2025 | Jornay Pm |
| Phathom Pharmaceuticals, INC. | $71.89 | 2025 | Voquezna |
| Ironshore Pharmaceuticals INC. | $62.06 | 2023-2024 | Jornay Pm |
| Amgen INC. | $61.62 | 2023-2024 | Repatha, Otezla, Prolia |
| Mylan Specialty L.P. | $46.87 | 2022-2023 | Yupelri |
| Baxter Healthcare | $42.64 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $39.05 | 2025 | Caplyta |
| Axsome Therapeutics, INC. | $37.21 | 2023-2024 | Auvelity |
| Harmony Biosciences LLC | $35.69 | 2022-2023 | Wakix |
| Supernus Pharmaceuticals, INC. | $32.83 | 2023-2024 | Qelbree, Qelbree |
| United Therapeutics Corporation | $32.79 | 2022 | |
| Electromed, INC. | $28.38 | 2022 | |
| Inspire Medical Systems, INC. | $28.35 | 2025 | Inspire |
| Sanofi-Aventis U.S. LLC | $28.07 | 2025 | |
| Corium, LLC | $27.01 | 2023 | Azstarys |
| Azurity Pharmaceuticals, INC. | $23.71 | 2025 | Zonisade |
| Alk-Abello, INC | $22.57 | 2025 | Neffy |
| Novartis Pharmaceuticals Corporation | $22.16 | 2024 | |
| Pulmonx Corporation | $21.29 | 2023 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Viatris Specialty LLC | $21.24 | 2025 | Yupelri |
| Noven Therapeutics, LLC | $17.62 | 2025 | Xelstrym |
| Resmed Corp | $16.61 | 2021 | |
| Neos Therapeutics, LP | $16.17 | 2024 | Adzenys Xr-Odt |
| Tactile Systems Technology INC | $15.80 | 2022 | |
| Pfizer INC. | $13.98 | 2025 | |
| Sumitomo Pharma America, INC. | $13.18 | 2023 | Gemtesa |
| Merck Sharp & Dohme LLC | $12.88 | 2022 | |
| Jazz Pharmaceuticals INC. | $12.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Buncher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.